TY - JOUR
T1 - Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes
T2 - A meta-analysis update
AU - Salah, Husam M.
AU - Al'Aref, Subhi J.
AU - Khan, Muhammad Shahzeb
AU - Al-Hawwas, Malek
AU - Vallurupalli, Srikanth
AU - Mehta, Jawahar L.
AU - Mounsey, J. Paul
AU - Greene, Stephen J.
AU - McGuire, Darren K.
AU - Lopes, Renato D.
AU - Fudim, Marat
N1 - Funding Information:
Al'Aref: Supported by NIH 2R01 HL127661-05, receives royalty fees from Elsevier.
Funding Information:
Mehta has previously served as consultant to Bayer, Boehringer Ingelheim, AstraZeneca, MedImmmune and Pfizer; and received grant support from Bayer, Boehringer Ingelheim and AstraZeneca. Current grant support from Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (Washington, DC, USA) (grant No BX-000282-05). Greene: has received a Heart Failure Society of America/ Emergency Medicine Foundation Acute Heart Failure Young Investigator Award funded by Novartis; receives research support from Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and Novartis; serves on advisory boards for Amgen and Cytokinetics; and serves as a consultant for Amgen and Merck. McGuire: has received personal fees for trial leadership and/or consultancy from Boehringer Ingelheim, Janssen Research and Development LLC, Sanofi US, Merck Sharp and Dohme Corp., Eli Lilly USA, Novo Nordisk, GlaxoSmithKline, AstraZeneca, Lexicon Pharmaceuticals, Eisai, Pfizer, Metavant, Applied Therapeutics, Afimmune and Esperion. Lopes: research grants and personal fees from Bristol-Myers Squibb and Pfizer, personal fees from Boehringer Ingelheim and Bayer AG and grants from Amgen Inc, GlaxoSmithKline, Medtronic PLC, and Sanofi Aventis outside the submitted work. Fudim: Supported by the Mario Family Award, Translating Duke Health Award; Duke Medicine Chair's Award, consulting fees from AstraZeneca, AxonTherapies, CVRx, Daxor, Edwards LifeSciences, Galvani, NXT Biomedical and Respicardia.
PY - 2021/3
Y1 - 2021/3
N2 - In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.
AB - In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.
UR - http://www.scopus.com/inward/record.url?scp=85099472749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099472749&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2020.12.007
DO - 10.1016/j.ahj.2020.12.007
M3 - Letter
C2 - 33385359
AN - SCOPUS:85099472749
VL - 233
SP - 86
EP - 91
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
ER -